NL-OMON34283
Completed
Not Applicable
Study of the Safety, Tolerability and Pharmacokinetics of LY2623091 after Single Oral Dosing in Healthy Subjects - LY2623091 SAD study
Chorus LRL (Division of Eli Lilly)0 sites18 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Chorus LRL (Division of Eli Lilly)
- Enrollment
- 18
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Healthy men and women ((postmenopausal/sterilized)
- •\- 18 \- 65 years of age, inclusive;
- •\- BMI \< 32\.5 kg/m2;
- •\- Non smoking or smoking lesss than 10 cigarettes/day
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance after Multiple Oral Dosing of LY2623091 in Healthy Volunteerschronic kidney diseaseKidney failure10038430NL-OMON36630Eli Lilly32
Completed
Not Applicable
Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects with Painful Lumbar Radiculopathylow back painPainful Lumbar Radiculopathy10041543NL-OMON40320Biogen Idec78
Active, not recruiting
Phase 1
Pediatric PK Study (POS IV and PFS)Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia.Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2014-002807-10-CZMerck Sharp & Dohme Corp.84
Active, not recruiting
Phase 1
Pediatric PK Study (POS IV and PFS)EUCTR2014-002807-10-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.118
Active, not recruiting
Phase 1
Pediatric PK Study (POS IV and PFS)Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia.MedDRA version: 18.0 Level: HLGT Classification code 10017528 Term: Fungal infectious disorders System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2014-002807-10-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.118